Certis Biologicals

Columbia, Maryland

Classification

Private

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

About

About

Certis Biologicals is a biotechnology company founded in 2001 by Mitsui & Co. through the acquisition of Thermo Trilogy Corporation, with its headquarters located in Columbia, Maryland. The company traces its origins to the mid-1990s development of biological and botanical pesticides, including the formation of Thermo Trilogy in 1996 and the acquisition of Neem Technologies from W.R. Grace. It rebranded from Certis USA to Certis Biologicals in 2021 to emphasize its focus on biological innovations and global distribution of biopesticides. Business/Product Breakdown Certis Biologicals develops, manufactures, and distributes biopesticides and related biological solutions for organic and conventional crop protection, targeting pests, diseases, and weeds in commercial agriculture, turf, greenhouses, and home and garden applications. The portfolio includes biofungicides and bactericides such as Convergence, Double Nickel, Howler EVO, and KOCIDE 3000-O for controlling fungal and bacterial diseases through mechanisms like rhizosphere colonization and microbiome enhancement; biological plant activators like LifeGard WG to trigger plant resistance genes against foliar infections; bionematicides such as NemaClean to target plant-parasitic nematodes across life stages; and bioinsecticides including Bt-based products and neem-derived formulations like Trilogy for insect and mite control. These residue-exempt, OMRI-listed products support integrated pest management programs, offering short re-entry intervals, zero-day pre-harvest intervals, and compatibility with conventional chemistries, while production occurs at three dedicated facilities in the United States and India focused on fermentation and neem extraction. The company exports to more than 50 countries and collaborates with partners like Certis-Belchim for regulatory approvals, Belchim Crop Protection Canada for distribution, and technology providers such as AgBiome and Bayer CropScience to expand solutions for row crops including corn, soybeans, peanuts, fruits, vegetables, and nuts.

Keywords

Keywords

Classified

Private